Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy

por Hibma, Jennifer E., Jayachandran, Priya, Neelakantan, Srividya, Harnisch, Lutz O.
Publicado 2023

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin

por Fostvedt, Luke K., Hibma, Jennifer E., Masters, Joanna C., Vandendries, Erik, Ruiz‐Garcia, Ana
Publicado 2019

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

por Ruiz-Garcia, Ana, Tan, Weiwei, Li, Jerry, Haughey, May, Masters, Joanna, Hibma, Jennifer, Lin, Swan
Publicado 2020

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

por Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Publicado 2021

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

por Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Publicado 2022

Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer

por Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer
Publicado 2021